tucatinib,trastuzumab
seagen
['crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bcsm', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
the #oncoalerttoptweet day1 of #asco23 tweet by our oncoalert faculty #her2 in cholangiocarcinoma - biliary tract cancers . tucatinib plus trastuzumab already approved in #bcsm #crcsm. best 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨